Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined

NCT ID NCT07683221

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new treatment approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants receive targeted radiation therapy followed by a combination of two immunotherapy drugs (ipilimumab N01 and sintilimab) plus standard chemotherapy (nab-paclitaxel and gemcitabine). The goal is to see if this powerful mix can delay cancer growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic body radiotherapy, ipilimumab N01, sintilimab, nab-paclitaxel, gemcitabine
What this could lead to
If successful, this combination approach could offer a new treatment option that extends survival and controls tumor growth in patients with locally advanced pancreatic cancer.
What could go wrong
This is an early-phase, single-arm trial with only 47 participants, so results may not apply broadly. The combination of therapies may cause significant side effects, and the treatment may not improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shandong Cancer Hospital and Institute

    Jinan, Shandong, 0531, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.